Top-Rated Stocks NYSE:GMED Globus Medical - GMED Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $76.96 -0.92 (-1.18%) (As of 02/8/2023 05:07 PM ET) Add Compare Share Share Today's Range$76.96▼$78.5850-Day Range$68.95▼$79.6352-Week Range$52.60▼$81.78Volume629,577 shsAverage Volume467,380 shsMarket Capitalization$7.68 billionP/E Ratio50.97Dividend YieldN/APrice Target$79.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Globus Medical MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside2.3% Upside$79.00 Price TargetShort InterestBearish6.32% of Float Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.23Based on 6 Articles This WeekInsider TradingSelling Shares$2.82 M Sold Last QuarterProj. Earnings Growth14.29%From $2.03 to $2.32 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector444th out of 1,029 stocksSurgical & Medical Instruments Industry46th out of 105 stocks 1.4 Analyst's Opinion Consensus RatingGlobus Medical has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $79.00, Globus Medical has a forecasted upside of 2.3% from its current price of $77.21.Amount of Analyst CoverageGlobus Medical has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.32% of the float of Globus Medical has been sold short.Short Interest Ratio / Days to CoverGlobus Medical has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Globus Medical has recently increased by 2.11%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGlobus Medical does not currently pay a dividend.Dividend GrowthGlobus Medical does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlobus Medical has received a 57.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Synthetic bone grafts", "Artificial joints", and "Robotic surgery systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Globus Medical is -0.93. Previous Next 1.8 News and Social Media Coverage News SentimentGlobus Medical has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Globus Medical this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,824,984.00 in company stock.Percentage Held by Insiders24.41% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.23% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Globus Medical are expected to grow by 14.29% in the coming year, from $2.03 to $2.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Globus Medical is 51.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.70.Price to Earnings Ratio vs. SectorThe P/E ratio of Globus Medical is 51.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 112.83.Price to Earnings Growth RatioGlobus Medical has a PEG Ratio of 2.96. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGlobus Medical has a P/B Ratio of 4.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Globus Medical (NYSE:GMED) StockGlobus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.Read More Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address GMED Stock News HeadlinesFebruary 8, 2023 | americanbankingnews.comKeith W. Pfeil Sells 29,167 Shares of Globus Medical, Inc. (NYSE:GMED) StockFebruary 3, 2023 | finance.yahoo.comStrength Seen in Nevro (NVRO): Can Its 5.1% Jump Turn into More Strength?February 8, 2023 | Vantage Point (Ad)Predict These Market Breakouts with A.I.We’re looking for breakouts using a simple A.I. tool that you've got to see in our Live Free A.I. Market Training. Breakouts can make or break your trading, so it's critical you know how to predict them 1 - 3 days ahead. They happen at any moment, and they're easier to find with A.I. on your side. February 2, 2023 | finance.yahoo.comGlobus Medical Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference CallJanuary 16, 2023 | finance.yahoo.comHere's Why Investors Should Retain Globus Medical (GMED) StockJanuary 14, 2023 | finance.yahoo.com15 Largest Orthopedic Companies in the WorldJanuary 11, 2023 | finance.yahoo.comGlobus Medical, Inc. (NYSE:GMED) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?January 8, 2023 | seekingalpha.comGlobus Medical: An Impressive Long-Term Revenue Growth PlayFebruary 8, 2023 | Vantage Point (Ad)Predict These Market Breakouts with A.I.We’re looking for breakouts using a simple A.I. tool that you've got to see in our Live Free A.I. Market Training. Breakouts can make or break your trading, so it's critical you know how to predict them 1 - 3 days ahead. They happen at any moment, and they're easier to find with A.I. on your side. January 6, 2023 | markets.businessinsider.com7 Analysts Have This to Say About Globus MedicalDecember 30, 2022 | finance.yahoo.comGlobus Medical (GMED) Global Growth Strong Despite Margin WoeDecember 12, 2022 | msn.comWells Fargo Maintains Overweight Rating for Globus Medical: Here's What You Need To KnowNovember 18, 2022 | seekingalpha.comGlobus Medical: Retain Buy With EPS Upside, Seeking Objectives Of $86, $106November 17, 2022 | finance.yahoo.comGlobus Medical Partners with the UK’s NHS to Provide Hospitals with Surgical Robotic Navigation TechnologyNovember 14, 2022 | finance.yahoo.comGlobus Medical's (NYSE:GMED) five-year earnings growth trails the favorable shareholder returnsNovember 14, 2022 | finance.yahoo.comGlobus Medical (GMED) Q3 Earnings Miss Estimates, EPS View CutNovember 10, 2022 | finance.yahoo.comCompany News for Nov 10, 2022November 9, 2022 | markets.businessinsider.comNeedham Reaffirms Their Buy Rating on Globus Medical (GMED)November 9, 2022 | seekingalpha.comGlobus Medical, Inc. (GMED) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Globus Medical (GMED)November 8, 2022 | finance.yahoo.comGlobus Medical Reports Third Quarter 2022 ResultsNovember 8, 2022 | finance.yahoo.comGlobus Medical (GMED) Q3 Earnings Lag EstimatesNovember 7, 2022 | msn.comGlobus Medical's Earnings OutlookNovember 1, 2022 | finance.yahoo.comOrthoPediatrics (KIDS) Reports Q3 Loss, Lags Revenue EstimatesSeptember 14, 2022 | money.usnews.comGlobus Medical Inc - Ordinary Shares - Class ASeptember 12, 2022 | nasdaq.comGlobus Medical (GMED) Gains Market Share, Cost Woes StaySeptember 6, 2022 | finance.yahoo.comCould Globus Medical Be the Best Healthcare Stock?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address GMED Company Calendar Last Earnings11/04/2021Today2/08/2023Next Earnings (Confirmed)2/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:GMED CUSIP37957720 CIK1237831 Webwww.globusmedical.com Phone(610) 930-1800Fax610-930-2042Employees2,400Year FoundedN/APrice Target and Rating Average Stock Price Forecast$79.00 High Stock Price Forecast$91.00 Low Stock Price Forecast$71.00 Forecasted Upside/Downside+2.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$1.51 Trailing P/E Ratio50.97 Forward P/E Ratio37.91 P/E Growth2.96Net Income$149.19 million Net Margins15.55% Pretax Margin20.11% Return on Equity11.59% Return on Assets10.32% Debt Debt-to-Equity RatioN/A Current Ratio6.33 Quick Ratio4.39 Sales & Book Value Annual Sales$958.10 million Price / Sales8.02 Cash Flow$2.80 per share Price / Cash Flow27.49 Book Value$17.15 per share Price / Book4.49Miscellaneous Outstanding Shares99,840,000Free Float75,471,000Market Cap$7.68 billion OptionableOptionable Beta0.99 Key ExecutivesDaniel T. ScavillaPresident, Chief Executive Officer & DirectorKeith W. PfeilCFO, Chief Accounting Officer & Senior VPKelly G. HullerSecretary, Senior VP & General CounselBrian KearnsSenior Vice President-Business DevelopmentKey CompetitorsIntegra LifeSciencesNASDAQ:IARTTeleflexNYSE:TFXNuVasiveNASDAQ:NUVAAtriCureNASDAQ:ATRCAbiomedNASDAQ:ABMDView All CompetitorsInsiders & InstitutionsRussell Investments Group Ltd.Sold 665 shares on 2/8/2023Ownership: 0.022%Arizona State Retirement SystemBought 190 shares on 2/8/2023Ownership: 0.022%Nuance Investments LLCBought 3,369 shares on 2/8/2023Ownership: 0.012%Commonwealth Equity Services LLCSold 171 shares on 2/7/2023Ownership: 0.006%Benjamin Edwards Inc.Bought 150 shares on 2/7/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions GMED Stock - Frequently Asked Questions Should I buy or sell Globus Medical stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GMED shares. View GMED analyst ratings or view top-rated stocks. What is Globus Medical's stock price forecast for 2023? 8 equities research analysts have issued 1-year price targets for Globus Medical's shares. Their GMED share price forecasts range from $71.00 to $91.00. On average, they expect the company's stock price to reach $79.00 in the next year. This suggests a possible upside of 1.4% from the stock's current price. View analysts price targets for GMED or view top-rated stocks among Wall Street analysts. How have GMED shares performed in 2023? Globus Medical's stock was trading at $74.27 at the beginning of 2023. Since then, GMED stock has increased by 4.9% and is now trading at $77.88. View the best growth stocks for 2023 here. Are investors shorting Globus Medical? Globus Medical saw a decrease in short interest during the month of December. As of December 30th, there was short interest totaling 4,750,000 shares, a decrease of 5.6% from the December 15th total of 5,030,000 shares. Based on an average daily volume of 588,800 shares, the days-to-cover ratio is currently 8.1 days. Approximately 6.2% of the shares of the company are sold short. View Globus Medical's Short Interest. When is Globus Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023. View our GMED earnings forecast. How can I listen to Globus Medical's earnings call? Globus Medical will be holding an earnings conference call on Tuesday, February 21st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Globus Medical's earnings last quarter? Globus Medical, Inc. (NYSE:GMED) posted its quarterly earnings results on Thursday, November, 4th. The medical device company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.45 by $0.05. The medical device company earned $229.72 million during the quarter, compared to the consensus estimate of $228.28 million. Globus Medical had a trailing twelve-month return on equity of 11.59% and a net margin of 15.55%. Globus Medical's revenue for the quarter was up 6.3% on a year-over-year basis. During the same period last year, the business posted $0.49 earnings per share. What guidance has Globus Medical issued on next quarter's earnings? Globus Medical issued an update on its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share guidance of $2.03-$2.03 for the period, compared to the consensus estimate of $2.10. The company issued revenue guidance of $1.02 billion-$1.02 billion, compared to the consensus revenue estimate of $1.02 billion. What is David Demski's approval rating as Globus Medical's CEO? 47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Globus Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA). What is Globus Medical's stock symbol? Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED." Who are Globus Medical's major shareholders? Globus Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include Geneva Capital Management LLC (1.43%), Paradigm Capital Management Inc. NY (0.67%), Boston Trust Walden Corp (0.66%), Pembroke Management LTD (0.59%), Allspring Global Investments Holdings LLC (0.40%) and Envestnet Asset Management Inc. (0.38%). Insiders that own company stock include Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas. View institutional ownership trends. How do I buy shares of Globus Medical? Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Globus Medical's stock price today? One share of GMED stock can currently be purchased for approximately $77.88. How much money does Globus Medical make? Globus Medical (NYSE:GMED) has a market capitalization of $7.78 billion and generates $958.10 million in revenue each year. The medical device company earns $149.19 million in net income (profit) each year or $1.51 on an earnings per share basis. How many employees does Globus Medical have? The company employs 2,400 workers across the globe. How can I contact Globus Medical? Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for the company is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042. This page (NYSE:GMED) was last updated on 2/8/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.